The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies

References

• Urlich C M, Bigler J, Potter J D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Rev Cancer 2006; 6: 130–140
   PubMed Web of Science ®Google Scholar
• De Groot D JA, de Vries E GE, Groen H JM, de Jong S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 2007; 61: 52–69
   PubMed Web of Science ®Google Scholar
• Herschman H R. Prostaglandins synthase 2. Biochim Biophys Acta 1996; 1299: 125–140
   PubMed Web of Science ®Google Scholar
• Shureiqi I, Chen D, Lee J J, Yang P, Newman R A, Brenner D E, Lotan R, et al. 15-LOX-1; a novel molecular target of non-steroidal anti-inflammatory drug – induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000; 92: 1136–1142
   PubMed Web of Science ®Google Scholar
• Kolluri S K, Corr M, James S Y, Bernasconi M, Lu D, Liu W, et al. The R-enantiomier of the nonosteroidal antiinflammatory drug etodolac binds retinoid x receptor and induces tumor selective apoptosis. Proc Natl Acad Sci 2005; 102: 2525–2530
   PubMed Web of Science ®Google Scholar
• Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, et al. The human multidrug resistance protein MFP4 functions as a prostaglandin efflux transporter and is inhibited by nonosteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003; 100: 9244–9249
   PubMed Web of Science ®Google Scholar
• Flick E D, Chan K A, Bracci P M, Holly E A. Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case–control study. Am J Epidemiol 2006; 164: 497–504
   PubMed Web of Science ®Google Scholar
• Holly E A, Lele C, Bracci P M, McGrath M S. Case–control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 1999; 150: 375–389
   PubMed Web of Science ®Google Scholar
• Baker J A, Weiss J R, Czuczman M S, Menezes R J, Ambrosone C B, Moysich K B. Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 2005; 16: 301–308
   PubMed Web of Science ®Google Scholar
• Beiderbeck A B, Holly E A, Sturkenboom M CIM, Coebergh J WW, Sticker B HCh, Leufkens H GM. Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma. Am J Epidemiol 2003; 157: 510–516
   PubMed Web of Science ®Google Scholar
• Cartwight R A, McKinney P A, O'Brien C, Richards I D, Roberts B, Lauder I, et al. Non-Hodkin's lymphoma: case–control epidemiological study in Yorkshire. Leuk Res 1988; 12: 81–88
   PubMed Web of Science ®Google Scholar
• Zhang Y, Holford T R, Leaderer B, Zahm S H, Boyle P, Morton L M. Prior medical conditions and medication use and risk of non-Hodgkin's lymphoma in Connecticut United States women. Cancer Causes Control 2004; 15: 419–428
   PubMed Web of Science ®Google Scholar
• Cerhan J R, Anderson K E, Janney C A, Vochon C M, Witzig T E, Habermann T M. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 2003; 106: 784–788
   PubMed Web of Science ®Google Scholar
• Bernstein L, Ross R K. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case–control study in Los Angeles County. Cancer Res 1992; 52(Suppl)5510s–5515s
   PubMed Web of Science ®Google Scholar
• Kato I, Koenig K L, Shore R E, Baptiste M S, Lilquist P P, Frizzera G, et al. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control 2002; 13: 965–974
   PubMed Web of Science ®Google Scholar
• Chang E T, Smedby K E, Hjalgrim H, Schollkopf C, Porwit-MacDonadl A, Sundstrom C. Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol 2005; 162: 965–974
   PubMed Web of Science ®Google Scholar
• Holly E A, Bracci P M. Population based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus negative participants in San Francisco. Am J Epidemiol 2003; 158: 316–327
   PubMed Web of Science ®Google Scholar
• Tavani A, La Vecchia C, Franceschi S, Serraino D, Carbone A. Medical history and risk of Hodgkin's and non-Hodgkin's lymphpoma. Eur J Cancer Rev 2000; 9: 59–64
   PubMed Web of Science ®Google Scholar
• Cerhan J R, Wallace R B, Folsom A R, Potter J D, Sellers T A, Zheng W, Lutz C T. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst 1997; 89: 314–328
   PubMed Web of Science ®Google Scholar
• Rauning U, Holme J A, Hongslo J K, Sram R. International commission for protection against environmental mutagens and carcinogens: an evaluation of the genetic toxicity of paracetamol. Mutation Res 1995; 327: 179–200
   PubMed Web of Science ®Google Scholar
• Chang E T, Zheng T, Weir E G, Borowitz M, Mann R B, Spiegelman D, et al. Aspirin and the risk of Hodgkin's lymphoma in a population based case control study. J Natl Cancer Inst 2004; 18: 305–315
   Web of Science ®Google Scholar
• Moysich K B, Bonner M R, Beehler G P, Marschal J R, Menezes R J, Baker J A. Regular analgesic use and risk of multiple myeloma. Leuk Res 2007; 31: 547–551
   PubMed Web of Science ®Google Scholar
• Pogoda J M, Katz J, McKean-Cowdin R, Nichols P W, Ross R K, Preston-Martin S. Prescription drug use and risk of acute myleoid leukemia by French, American, British subtype: results from a Los Angeles County case–control study. Int J Cancer 2005; 114: 634–638
   PubMed Web of Science ®Google Scholar
• Kasum C M, Blair C K, Folsom A R, Ross J A. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomarkers Prev 2003; 12: 534–537
   PubMed Web of Science ®Google Scholar
• Weiss J R, Baher J A, Baer M R, Menezes R J, Nowell S, Moysich K B. Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia. Leuk Res 2006; 30: 164–169
   PubMed Web of Science ®Google Scholar
• Traversa G, Menniti-Ipolito F, Da Cas R, Male A, Pulsoni A, Mandelli E. Drug use and acute leukemia. Pharmacoepidemiol Drug Saf 1998; 7: 113–123
   PubMed Web of Science ®Google Scholar
• Husain S S, Szabo I L, Tarnawski A S. NSAID inhibition of G1 cancer growth: clinical implications and molecular mechanism of action. Am J Gastroenterol 2002; 97: 543–553
   Google Scholar
• Marnett L J. Aspirin and related nonosteroidal antiinflammatory drugs as chemopreventive agents against colon. Cancer Prev Med 1995; 24: 103–106
   PubMed Web of Science ®Google Scholar
• Hull M A. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention. Eur J Cancer 2005; 41: 1854–1863
   PubMed Web of Science ®Google Scholar
• Hsu C S, Li Y. Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention. Biochem Biophys Res Commun 2002; 3: 705–709
   Google Scholar
• Sjodahl R. Extent mode and dose dependence of anticancer effects. Am J Med 2001; 110: 566–569
   Google Scholar
• Smith M L, Hawcroft G, Hull M A. The effect of non-steroidal antiinflammatory drugs on human colorectal cancer cells: evidence of different mechanism of action. Eur J Cancer 2000; 36: 664–674
   PubMed Web of Science ®Google Scholar
• Hsu A L, Ching F T, Wang D S, Song X, Rangnekar V M, Chen C S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397–11403
   PubMed Web of Science ®Google Scholar
• Ricchi P, Zarrilli R, Di Palma A, Acquaviva A M. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003; 88: 803–807
   PubMed Web of Science ®Google Scholar
• Nakamura S, Kobayashi M, Shibata K, Sahara N, Shigeno K, Shinjo K, et al. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Leuk Res 2006; 30: 123–135
   PubMed Web of Science ®Google Scholar
• Seo S K, Lee H C, Woo S H, Jin H O, Yoo D H, Lee S J, et al. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase induced mitochondrial dysfunction. Apoptosis 2007; 12: 195–209
   PubMed Web of Science ®Google Scholar
• Oshima M, Dinchuk J E, Kargman S L, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in APCdelta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996; 87: 803–809
   PubMed Web of Science ®Google Scholar
• Dannenberg A, Altorki N K, Boyle J O, Dang C, Howe L R, Weksler B B, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2: 544–551
   PubMed Web of Science ®Google Scholar
• Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733–1740
   PubMed Web of Science ®Google Scholar
• Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer induced angiogenesis. Ann Clin Lab Sci 2001; 31: 325–348
   PubMed Web of Science ®Google Scholar
• Masferrer J, Leahy K M, Koki A T, Zweifel B S, Settle S L, Woerner B M, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–1311
   PubMed Web of Science ®Google Scholar
• Thun M J, Henley S J, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002; 94: 252–266
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413–421
   PubMed Web of Science ®Google Scholar
• Fries S, Grosser T, Price T S, Lawson J A, Kapoor S, Demarco S, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006; 130: 55–64
   PubMed Web of Science ®Google Scholar
• Cervi D, Klement G, Stempak D, Baruchel S, Koki A, Ben-David Y. Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease. Clin Cancer Res 2005; 11(2 Part 1)712–719
   PubMed Web of Science ®Google Scholar
• Feng R, Lentzsch S. Treatment of multiple myeloma with SDX-308. Drug News Perspect 2007; 20: 431–435
   PubMed Web of Science ®Google Scholar
• Baz R, Hussein M A. Does low-dose aspirin have antineoplastic effects in multiple myeloma. Br J Hematol 2006; 134: 349–350
   PubMed Web of Science ®Google Scholar
• Robak P, Linke A, Cebula B, Robak T, Smolewski P. Cytotoxic effects of R-etadolac (SDX 101) in combination with purine analogs or monoclonal antibodies on exvivo B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2006; 47: 2625–2634
   PubMed Web of Science ®Google Scholar
• Bollosillo B, Pique M, Barragan M, Castano E, Villamor N, Colomer D. Aspirin and salicilate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998; 92: 1405–1414
   Google Scholar
• Klampfer L, Cammenga J, Wiśniewski H-G, Nimer S D. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 1999; 93: 2386–2394
   PubMed Web of Science ®Google Scholar
• Yasui H, Hideshima T, Anderson K C. Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia. Leuk Lymphoma 2006; 41: 2445–2446
   Web of Science ®Google Scholar
• Demerson C A, Humber L G, Abraham N A, Schilling G, Martell R R, Pace Asciak C, et al. Resolution of etadolac and antiinflammatory and prostaglandin synthetase inhibiting properties of enantiomers. J Med Chem 1983; 26: 1778–1780
   PubMed Web of Science ®Google Scholar
• Sheith K J, Brocks D R. Pharmacokinetic optimisation of the treatment of osteorthritis. Clin Pharmacokinet 1999; 26: 233–342
   Google Scholar
• Nardella F A, LeFevre J A. Enchanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac. Blood 2002; 99: 2625–2626
   PubMed Web of Science ®Google Scholar
• Jensen M, Engert A, Goebeler M B, Weissinger F, Wilhelm M, Osterborg A, et al. A novel pro-apoptotic agentSDX-101 (R-etodolac) for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Blood 2003; 102: 674a
   Web of Science ®Google Scholar
• Lu D, Zhao Y, Tawatao R, Cottam H B, Sen M, Leoni L M, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 3118–3123
   PubMed Web of Science ®Google Scholar
• Yasui H, Hideshima T, Ikeda H, Ocio E M, Kiziltepe T, Vallet S, et al. Novel etodolac analog SDX-308 (CEP-18082) induces cytotooxicity in multiple myeloma cells associated with inhibition of β-catenin/TCI pathway. Leukemia 2007; 21: 535–540
   PubMed Web of Science ®Google Scholar
• Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara M Y, et al. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 2007; 109: 2130–2138
   PubMed Web of Science ®Google Scholar
• Leoni L M, Crain B, Bailey B, Philips M, Bendall H, Chao Qi, et al. Mechanism of action and safety of second generation analogs of SDX-101 (R-etodolac). Blood 2004; 104: 930a, (abstract 3411)
   Web of Science ®Google Scholar
• Lindhagen E, Nissle S, Leoni L, Elliott G, Chao Q, Larsson K, et al. E-etodolac (SDX-101) and the related indole pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukemia cells. Cancer Chemother Pharmacol 2007; 60: 545–553
   PubMed Web of Science ®Google Scholar
• Ryan E P, Bushnell T P, Friedman A E, Rahman I, Phipps R P. Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione concert in Cancer. Immunol Immunother 2008; 57: 347–358
   PubMed Web of Science ®Google Scholar
• Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, et al. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs 2008; 26: 139–149
   PubMed Web of Science ®Google Scholar
• Ding J, Tsuboi K, Hoshikawa H, Goto R, Mori N, Katsukawa M, et al. Cyclooxygenase isozymes are expressed in human myeloma cells but not involved in antiproliferative effect of cyclooxygenase inhibitors. Mol Carcinog 2006; 45: 250–259
   PubMed Web of Science ®Google Scholar
• Yasui H, Hideshima T, Mamasaki M, Roccaro A M, Shiraishi N, Kumar S, et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity overcomes drug resistance and enhances the activity of dexamethasone in multiple myeloma. Blood 2005; 106: 706–712
   PubMed Web of Science ®Google Scholar
• Neri P, Yasu H, Hideshima T, Tassone N, Raje N, Laurence C P, et al. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glicocorticoid-resistant multiple myeloma cells. Br J Haematol 2006; 134: 37–44
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Elliott G, Roodman G D. SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies, including myeloma. Arch Pharm Chem Life Sci 2007; 340: 511–516
   PubMed Web of Science ®Google Scholar
• Truffinet V, Donnard M, Vincent C, Faucher J L, Bordessacle D, Turlure P, et al. Cyclooxygenase-1, but not-2 in blast cells of patients with acute leukemia. Int J Med 2007; 121: 924–927
   Google Scholar
• Vincen T C, Dounard M, Bordessoule D, Turlure P, Trimoreau F, Denizot Y. Cyclooxygenase-2 (COX-2) and blast cells of patients with acute leukemia. Leuk Res 2008; 32: 671–673
   PubMed Web of Science ®Google Scholar
• Rocca B, Morosetti R, Habib A, Maggiano N, Zassadowski F, Ciabattoni G, et al. Cyclooxygenase-1 but not-2 is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation. Leukemia 2004; 18: 1373–1379
   PubMed Web of Science ®Google Scholar
• Puhlmann U, Ziemann C, Ruedell G, Worwerk H, Schaefer D, Langebrake C, et al. Impact of cyclooxygenase system on doxorubicin – induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemia – HL-60 cells. J Pharmacol Exp Ther 2005; 312: 346–354
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Kamijo R, Takizawa K, Hatori M, Nagumo M. Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukemia cell lines. Eur J Cancer 2001; 37: 1570–1578
   PubMed Web of Science ®Google Scholar
• Cervi D, Truong A HL, Lee J S, Sukhai N, Li Y J, Koki A, Ben-David Y. Phosphorylation status of c-kit and Epo receptors and the presence of wild – type p53 conver in vitro resistance of murine erythroleukemic cells to Celecoxis. Oncogence 2004; 23: 2305–2314
   PubMed Web of Science ®Google Scholar
• Chao S-H, Wu A-B, Lee J, Chau F-A, Wang C-C. Anti-inflammatory effects of indomethacin S methyl ester derivative and induction of apoptosis in HL-60 cells. Biol Pharm Bull 2005; 28: 2206–2210
   PubMed Web of Science ®Google Scholar
• Czibere A, Prall W C, Zerbini L F, Crall F, Craigie E C, Ulrich S D, et al. The nonsteroidal anti-inflammatory drug exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome. Cell Cycle 2005; 4: 812–817
   PubMed Web of Science ®Google Scholar
• Arunasree K M, Roy K R, Anilkumar K, Aparna A, Reddy G V, Reddanna P. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: Role of COX-2 and MDR-1. Leuk Res 2008; 32: 855–864
   PubMed Web of Science ®Google Scholar